Correlation Between Supernus Pharmaceuticals and Dr Reddys

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Supernus Pharmaceuticals and Dr Reddys at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Supernus Pharmaceuticals and Dr Reddys into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Supernus Pharmaceuticals and Dr Reddys Laboratories, you can compare the effects of market volatilities on Supernus Pharmaceuticals and Dr Reddys and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Supernus Pharmaceuticals with a short position of Dr Reddys. Check out your portfolio center. Please also check ongoing floating volatility patterns of Supernus Pharmaceuticals and Dr Reddys.

Diversification Opportunities for Supernus Pharmaceuticals and Dr Reddys

-0.51
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Supernus and RDY is -0.51. Overlapping area represents the amount of risk that can be diversified away by holding Supernus Pharmaceuticals and Dr Reddys Laboratories in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dr Reddys Laboratories and Supernus Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Supernus Pharmaceuticals are associated (or correlated) with Dr Reddys. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dr Reddys Laboratories has no effect on the direction of Supernus Pharmaceuticals i.e., Supernus Pharmaceuticals and Dr Reddys go up and down completely randomly.

Pair Corralation between Supernus Pharmaceuticals and Dr Reddys

Given the investment horizon of 90 days Supernus Pharmaceuticals is expected to generate 1.56 times more return on investment than Dr Reddys. However, Supernus Pharmaceuticals is 1.56 times more volatile than Dr Reddys Laboratories. It trades about 0.11 of its potential returns per unit of risk. Dr Reddys Laboratories is currently generating about -0.25 per unit of risk. If you would invest  3,416  in Supernus Pharmaceuticals on August 28, 2024 and sell it today you would earn a total of  194.00  from holding Supernus Pharmaceuticals or generate 5.68% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Supernus Pharmaceuticals  vs.  Dr Reddys Laboratories

 Performance 
       Timeline  
Supernus Pharmaceuticals 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Supernus Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy basic indicators, Supernus Pharmaceuticals is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.
Dr Reddys Laboratories 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Dr Reddys Laboratories has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Supernus Pharmaceuticals and Dr Reddys Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Supernus Pharmaceuticals and Dr Reddys

The main advantage of trading using opposite Supernus Pharmaceuticals and Dr Reddys positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Supernus Pharmaceuticals position performs unexpectedly, Dr Reddys can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dr Reddys will offset losses from the drop in Dr Reddys' long position.
The idea behind Supernus Pharmaceuticals and Dr Reddys Laboratories pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets